Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562650 · ClinicalTrials.gov registry record · NA
Text Message Treatment for Social Anxiety
A NA study of Social Anxiety, sponsored by Florida State University.
- Completed
- Registry status
- NA
- Development phase
- 97
- Enrollment target
- 1
- Study location
NCT03562650: Completed NA study of Social Anxiety, sponsored by Florida State University.
NCT03562650 is a NA study of Social Anxiety that has completed, run by Florida State University. The registered enrollment target is 97 participants, below the 600-participant average among 3 other Social Anxiety trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03562650, a NA study of Social Anxiety, has completed, sponsored by Florida State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 97 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an intervention study designed to evaluate a text message based safety behavior fading treatment for people with social anxiety disorder.
Primary Outcome
Self-report scale that measures Social anxiety symptoms. Scores range from 0 to 68 with higher scores indicating higher levels of social anxiety symptoms.
Conditions Studied
Interventions
- BEHAVIORAL Safety Behavior Fading
- BEHAVIORAL Present Centered
Study Locations (1)
Florida
- Florida State University, Department of Psychology - Tallahassee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2018-01-27 |
| Est. Completion | 2019-03-27 |
| Phase | NA |
What the finished NCT03562650 record still lists
NCT03562650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 600-participant average among 3 other Social Anxiety trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Social Anxiety appearing as the primary indexed condition, and to 2 interventions - of which Safety Behavior Fading is the first listed.
NCT03562650 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03562650 about?
NCT03562650 is a clinical study titled "Text Message Treatment for Social Anxiety". This is an intervention study designed to evaluate a text message based safety behavior fading treatment for people with social anxiety disorder.
What is the current status of trial NCT03562650?
This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2018-01-27. Estimated completion is 2019-03-27.
What conditions does trial NCT03562650 study?
This clinical trial studies the following conditions: Social Anxiety.
What interventions are being tested in trial NCT03562650?
The interventions under investigation include: Safety Behavior Fading (BEHAVIORAL), Present Centered (BEHAVIORAL).
Who is sponsoring clinical trial NCT03562650?
This trial is sponsored by Florida State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03562650 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Social Anxiety
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI